secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001104659-22-058228
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M
--------------------------------------------------------------------------------

- Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.
- Net loss of $1.4M ($0.08/share) vs net income $0.3M ($0.03) in Q1 2021; adjusted EBITDA $2.3M vs $1.2M.
- First patient dosed in Phase 3 trial for DFD-29 for papulopustular rosacea; one additional product launch planned in H2 2022.
- Expanded product portfolio with Amzeeq and Zilxi launches; now 9 marketed prescription dermatology products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/0001104659-22-058228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922058228/tm2214972d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-058228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer